Prospective, Phase I/II, Non-randomized, Open Label, Multicenter Study to Determine Safety and Efficacy of Nilotinib in a Population With Steroid-refractory/or Steroid-dependent cGVHD

Trial Profile

Prospective, Phase I/II, Non-randomized, Open Label, Multicenter Study to Determine Safety and Efficacy of Nilotinib in a Population With Steroid-refractory/or Steroid-dependent cGVHD

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Jul 2016

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GITMO; Nilo-cGVHD
  • Most Recent Events

    • 02 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Mar 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to recruiting.
    • 20 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top